How Doctors Manage Polivy's Side Effects
Polivy (polatuzumab vedotin), used for relapsed or refractory diffuse large B-cell lymphoma, causes side effects like peripheral neuropathy, neutropenia, fatigue, diarrhea, and infusion reactions. These are managed through dose adjustments, premedication, and supportive care. Doctors often reduce the dose by 20-30% for grade 2+ neuropathy or cytopenias, delay infusions if needed, or discontinue for severe cases. Prophylactic G-CSF prevents neutropenia, while antihistamines and acetaminophen before infusions cut reaction risks.[1][2]
Handling the Most Common Issue: Peripheral Neuropathy
Up to 40% of patients experience neuropathy, often sensory (numbness, tingling). Management includes:
- Early monitoring with neuropathy scales during cycles.
- Dose holds or reductions at grade 2 severity.
- Symptom relief with gabapentin, duloxetine, or pregabalin.
- Stopping Polivy if grade 3+ persists. Symptoms improve or resolve in most after treatment ends.[2][3]
Reducing Infusion Reactions and Infections
Infusion reactions (13-19%) drop with premeds like dexamethasone, acetaminophen, and diphenhydramine. For infections from neutropenia (40%+ risk), G-CSF prophylaxis is standard, plus antivirals or antifungals as needed. Hydration and anti-diarrheals control GI effects.[1][2]
What If Side Effects Persist?
Persistent issues lead to treatment interruption or switch to alternatives like CAR-T therapy. Patient monitoring via weekly bloodwork and neuro exams helps catch problems early. Real-world data shows 70-80% complete planned cycles with adjustments.[3]
Patient Tips for Coping
Stay hydrated, report tingling or fever immediately, and use over-the-counter aids for nausea/fatigue. Clinical trials emphasize multidisciplinary care (oncologist + neurologist).[2]
Sources:
[1] Polivy Prescribing Information, Genentech (https://www.gene.com/download/pdf/polivy_prescribing.pdf)
[2] NCCN Guidelines for B-Cell Lymphomas, Version 2023
[3] Journal of Clinical Oncology, Polivy Trials (e.g., GO29365 study analysis) (https://ascopubs.org/doi/full/10.1200/JCO.20.00963)